Quantum‐Capacitance Biosensing Enables Real‐Time Monitoring of Naxitamab for Therapeutic Response Stratification in Neuroblastoma
Open Access
- 31 July 2026
- journal article
- research article
- Published by Wiley in Small Science
- Vol. 6 (8) , e70349
Abstract
Neuroblastoma, a leading cause of cancer‐related mortality in early childhood, relies on anti‐GD2 immunotherapy, whose efficacy is critically dependent on systemic drug exposure that remains largely unmonitored in real time, limiting treatment optimization and early response assessment. Here, a first‐in‐class, label‐free electrochemical biosensing platform is reported for the direct quantification of naxitamab in patient‐derived samples. The system is based on a laser‐assisted reduced graphene oxide–gold nanoparticle (rGO@AuNPs) nanocomposite, enabling ultrasensitive detection through quantum capacitance modulation arising from perturbations in the electronic density of states of graphene upon biomolecular recognition. Laser‐assisted fabrication yields nanostructured electrodes with enhanced surface area and conductivity, promoting stable antibody immobilization and reproducible signal transduction. The platform operates in the femtomolar regime, with a linear response between 25 and 300 fM, high specificity against relevant interferents, and robust performance in diluted human serum. A single‐point calibration strategy enables accurate quantification while compensating for device variability. Application to retrospective clinical samples reveals distinct post‐infusion concentration profiles, enabling early discrimination between responder groups and detection of antidrug antibody development. This work establishes quantum‐capacitance biosensing as a generalizable strategy for real‐time monitoring of therapeutic antibodies in precision oncology.Keywords
This publication has 35 references indexed in Scilit:
- Laser‐Assisted In Situ Fabrication of rGO/Bi 2 O 3 Nanocomposites for Heavy Metal SensingSmall, 2026
- TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic–Pharmacoeconomic EvaluationClinical Pharmacokinetics, 2025
- The quantum mechanical origin of the supercapacitance phenomenon in reduced graphene oxide structuresCarbon, 2024
- Reduced graphene oxide electrodes meet lateral flow assays: A promising path to advanced point-of-care diagnosticsBiosensors and Bioelectronics, 2024
- Guidelines for outpatient administration of naxitamab: Experience from Atrium Health Levine Children's HospitalCancer Medicine, 2024
- Capacitive immunosensing at gold nanoparticle-decorated reduced graphene oxide electrodes fabricated by one-step laser nanostructurationBiosensors and Bioelectronics, 2024
- Immunotherapy for Neuroblastoma2019
- Pharmacokinetics of the chimeric anti-GD2 antibody, ch14.18, in children with high-risk neuroblastomaCancer Chemotherapy and Pharmacology, 2014
- Electrochemical Desorption of Proteins from Gold Electrode SurfaceElectroanalysis, 2006
- Disialoganglioside GD2 anti‐idiotypic monoclonal antibodiesInternational Journal of Cancer, 1993